I think it will trade sideways (dead) for a year until the Ponatinib results are released (they will NOT stop the trial - it's been widely discussed here by some of the most knowledgeable posters (exwannabe) who has detailed why they cannot stop the trial short). ..ergo.. put money to work somewhere else, and buy ARIA a month ahead of Pona news.
Sure, you might get a surge here and there, but it will be a tradinng range between 3-6, trending closer to the low end.
Just my opinion, but I've seen it before, unfortunately.
ARIA stock is more dependent on Ridaforolimus than a lot of people are giving it credit for.